Shanghai’s Tough Proposals For Medical Sales Reps Draw Ire
Executive Summary
Shanghai is significantly tightening its grip on pharma commercial activities with two new rules in August. One restricts medical sales reps from visiting physicians outside a pre-set time and location, and another requires drug makers to register their sales reps with the local FDA.
You may also be interested in...
Mooncakes Under The Sun: Can China's ‘Name And Shame’ Rule Create Level Playing Field?
China's proposal to register all medical sales reps could lead to the eventual elimination of kickbacks to physicians. Experts say it's the first step towards creating a level compliance playground for multinational and domestic drug makers.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.